Rates of expansion and differentiation properties in vivo of HSCs reflect their developmental status. (A) Experimental design used to assess HSC regeneration kinetics in serially transplanted mice. In each HSC regeneration experiment, the initial transplant of unseparated cells contained ≈10 HSCs based on prior determination of the HSC content of the test cell suspension being used. These cells were then injected into sublethally irradiated Ly5-congenic W41/W41 recipients. This experimental design was used to maximize the contribution of the transplanted HSCs to the total HSC pool being regenerated while still allowing donor HSCs to be definitively identified, and also to remove any influences related to variable input HSCs doses that have been previously reported (17). The blue asterisks denote the groups of mice whose cells were analyzed 16 weeks posttransplant to demonstrate changes in the proportional contribution of mature myeloid cells to the total WBCs generated from the transplanted HSCs. (B) Comparison of HSC regeneration (mean ± SEM CRUs/mouse, four experiments each) from E14.5 fetal liver (FL, gray symbols) and adult bone marrow (ABM, black symbols) in sublethally irradiated W41/W41 mice injected initially with 10 HSCs (CRUs). (C) Similar analyses of mice transplanted with 10 HSCs (CRUs) from E18.5 fetal bone marrow (E18.5 FBM, pink symbols) and 3- and 4-week postnatal bone marrow (3-wk BM, red symbols; 4-wk BM, blue symbols). (D) HSCs (CRUs) produced from the HSC progeny of E14.5 fetal liver HSCs after 6 weeks in primary recipients (FL-derived, green symbols). (E) Relative outputs of donor-derived lymphoid and myeloid WBCs 16 weeks posttransplant in recipients of 3–6 CRUs. Each bar shows the mean ± SEM percentage of all donor-derived WBCs that expressed Ly6g and/or Mac1 (GM, n = 4–24). The information in the brackets in the labels for each bar refers to the number of weeks that were allowed to elapse before cells were harvested from primary recipients injected with the initial cells indicated and then transferred to secondary (or, in the case of the bottom bar, also into tertiary) recipients where the final lineage output assessments were made 16 weeks later. ∗, Values significantly lower (P < 0.05) than the value obtained for transplants of E14.5 fetal liver HSCs (CRUs). ∗∗, Values significantly higher (P < 0.05) than the value obtained for transplants of adult bone marrow HSCs (CRUs). (F) Representative FACS plots of the WBCs in mice 16 weeks after being transplanted with HSCs from 3-week (red) or 4-week (blue) postnatal bone marrow.